



## Curriculum Vitae Europass



### Personal informations

Name(s) / Surname(s) **Maria Gabriella Matera**  
Address() Parco Margherita, 24 Napoli 80121  
Phone(s) ++390815665825  
Fax ++390815666462  
E-mail mariagabriella.matera@unicampania.it  
citizenship Italian

### Professional experience

Occupation or position Professor BIO/14 Department Experimental Medicine Campania University Luigi Vanvitelli  
Visiting professor in pharmacological sciences of King's College of London  
President of the Degree of Medical Scientific Informant  
Principal activities Respiratory Medicine researcher  
Name and address of the employer University Luigi Vanvitelli  
Sector BIO/14

### Instruction and Formation

Date 1990 PhD in Pharmacology and Toxicology  
1986 Specialization in Clinical Pharmacology cum laude  
1982 Degree in Medicine and Surgery cum laude  
Title of qualification Degree in Medicine and Surgery; Specialization in Pharmacology; PhD in Pharmacology and Toxicology  
Principal subjects / professional skills University teaching  
Preclinical and clinical researches  
Name and type of organization providing education and training University  
level in national or international classification 2 World expert on bronchodilators  
<http://www.expertscape.com/ex/bronchodilators> University Palo Alto California  
FERS (Fellowship European Respiratory Society)

### Personal skills and competences

Mother tongue **italian**  
Other tongue(s) **English and French**

Self evaluation <i>European level</i>	<b>Comprehension</b>				<b>Spoken</b>				<b>Written</b>	
	Listen		Lecture		Oral interaction		Oral production			
	X	Great	X	Great	X	Great	X	Great	X	Great
<b>English</b>	X	Great	X	Great	X	Great	X	Great	X	great
<b>French</b>	X	Great	X	Great	X	Great	X	Great	X	great

#### Further informations

Associated Editor Pulmonary Pharmacology and Therapeutics  
 Associate Editor BMC Pulmonary Medicine  
 Component Board Therapeutic Advances in Respiratory Diseases  
 Component Board Editoriale Pharmacology and Toxicology

Author n. 329 Scientific papers published on International reviewed journals JCR with I.F.

HI 41 (scopus)

n. citations=7353

## References of the last 20 years

1. Cazzola M, Ora J, Bianco A, Rogliani P, Matera MG. Guidance on nebulization during the current COVID-19 pandemic. *Respir Med.* 2021 Jan;176:106236. doi:10.1016/j.rmed.2020.106236.
2. Matera MG, Cazzola M, Page C. Prospects for COPD treatment. *Curr Opin Pharmacol.* 2021 Feb;56:74-84. doi: 10.1016/j.coph.2020.11.003.
3. Calzetta L, Matera MG, Coppola A, Rogliani P. Prospects for severe asthma treatment. *Curr Opin Pharmacol.* 2021 Feb;56:52-60. doi:10.1016/j.coph.2020.10.021.
4. Matera MG, Ora J, Calzetta L, Rogliani P, Cazzola M. Sex differences in COPD management. *Expert Rev Clin Pharmacol.* 2021 Mar;14(3):323-332. doi: 10.1080/17512433.2021.1888713.
5. Matera MG, Calzetta L, Ora J, Rogliani P, Cazzola M. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. *Expert Opin Drug Deliv.* 2021 Jan 19:1-16. doi: 10.1080/17425247.2021.1873271.
6. Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M. New Avenues for Phosphodiesterase Inhibitors in Asthma. *J Exp Pharmacol.* 2021 Mar 15;13:291-302. doi: 10.2147/JEP.S242961.
7. Cazzola M, Calzetta L, Matera MG. Long-acting muscarinic antagonists and small airways in asthma: Which link? *Allergy.* 2021 Feb 9. doi:10.1111/all.14766.
8. Cazzola M, Ora J, Cavalli F, Rogliani P, Matera MG. Treatable Mechanisms in Asthma. *Mol Diagn Ther.* 2021 Mar;25(2):111-121. doi: 10.1007/s40291-021-00514-w. Cazzola M, de Novellis V, Bianco A, Rogliani P, Matera MG. Disputes over the production and dissemination of misinformation in the time of COVID-19. *Respir Med.* 2021 Mar 29;182:106380. doi: 10.1016/j.rmed.2021.106380.
9. Cazzola M, Matera MG, Rogliani P, Calzetta L. Comparative studies of dual bronchodilation in COPD. *Monaldi Arch Chest Dis.* 2021 Feb 12;91(1). doi: 10.4081/monaldi.2021.1625.
10. Maniscalco M, Ambrosino P, Fuschillo S, Stufano S, Sanduzzi A, Matera MG, Cazzola M. Bronchodilator reversibility testing in post-COVID-19 patients undergoing pulmonary rehabilitation. *Respir Med.* 2021 Apr 13;182:106401. doi:10.1016/j.rmed.2021.106401.
11. Calzetta L, Ritondo BL, Coppola A, Matera MG, Di Daniele N, Rogliani P. Factors Influencing the Efficacy of COVID-19 Vaccines: A Quantitative Synthesis of Phase III Trials. *Vaccines (Basel).* 2021 Apr 1;9(4):341. doi: 10.3390/vaccines9040341.
12. Adiletta G, Baglioni S, Bettoncelli G, Bracciale P, Cazzola M, Clini EM, Cutrera R, D'Adduzio F, de Blasio F, Ferraro F, Fumagalli R, Lequaglie C, Matera MG, Numis F, Palange P, Picciolo S, Potena A, Romano F, Sabato E, Sacchetta A, Spatafora M, Stefanelli F, Zottola C. Comments on "Preventive

home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations" by

13. D'Amato *et al*. *Multidiscip Respir Med*. 2021 Apr 8;16(1):757. doi: 10.4081/mrm.2021.757.
14. Perrotta F, Matera MG, Cazzola M, Bianco A. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter? *Respir Med*. 2020 Jul;168:105996. doi: 10.1016/j.rmed.2020.105996.
15. Cazzola M, Matera MG. The effect of doxofylline in asthma and COPD. *Respir Med*. 2020 Apr;164:105904. doi: 10.1016/j.rmed.2020.105904.
16. Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, Cazzola M. Severe Asthma and Biological Therapy: When, Which, and for Whom. *Pulm Ther*. 2020 Jun;6(1):47-66. doi: 10.1007/s41030-019-00109-1.
17. Cazzola M, Stolz D, Rogliani P, Matera MG.  $\alpha$ -Antitrypsin deficiency and chronic respiratory disorders. *Eur Respir Rev*. 2020 Feb 12;29(155):190073. doi: 10.1183/16000617.0073-2019.
18. Matera MG, Rogliani P, Calzetta L, Cazzola M. TSLP Inhibitors for Asthma: Current Status and Future Prospects. *Drugs*. 2020 Apr;80(5):449-458. doi: 10.1007/s40265-020-01273-4.
19. Calzetta L, Ritondo BL, Matera MG, Cazzola M, Rogliani P. Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review. *Expert Rev Respir Med*. 2020 Jun;14(6):621-635. doi: 10.1080/17476348.2020.1743180.
20. Liccardi G, Calzetta L, Milanese M, Bilò MB, Liccardi MV, Matera MG, Rogliani P. Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? *Monaldi Arch Chest Dis*. 2020 Apr 8;90(1). doi: 10.4081/monaldi.2020.1233.
21. Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle *ex vivo*. *Br J Pharmacol*. 2020 Mar;177(5):1150-1163. doi: 10.1111/bph.14909.
22. Matera MG, Rinaldi B, Belardo C, Rinaldi M, Cazzola M. A review of the pharmacokinetics of M(3) muscarinic receptor antagonists used for the treatment of asthma. *Expert Opin Drug Metab Toxicol*. 2020 Jan 30:1-6. doi: 10.1080/17425255.2020.1716730.
23. Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P. A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. *Pulm Pharmacol Ther*. 2020 Feb;60:101883. doi: 10.1016/j.pupt.2019.101883.
24. Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and Therapeutics of Bronchodilators Revisited. *Pharmacol Rev*. 2020 Jan;72(1):218-252. doi: 10.1124/pr.119.018150. Review.
25. Calzetta L, Matera MG, Goldstein MF, Fairweather WR, Howard WW, Cazzola M, Rogliani P. A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study. *Pulm Pharmacol Ther*. 2020 Feb;60:101883. doi: 10.1016/j.pupt.2019.101883.
26. Cazzola M, Rogliani P, Matera MG. The future of bronchodilation: looking for new classes of bronchodilators. *Eur Respir Rev*. 2019 Dec 23;28(154). pii: 190095. doi: 10.1183/16000617.0095-2019. Print 2019 Dec 31. Review. PubMed PMID: 31871127.
27. Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, Lauro D. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. *Respir Med*. 2019 18;154:86-92. doi: 10.1016/j.rmed.2019.06.015.
28. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. *Trends Pharmacol Sci*. 2019;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27.
29. Matera MG, Calzetta L, Rogliani P, Cazzola M. Monoclonal antibodies for severe asthma: pharmacokinetic profiles. *Respir Med*. 2019;153:3-13. doi: 10.1016/j.rmed.2019.05.005.
30. Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis

- across erdosteine, carbocysteine, and N-acetylcysteine. *Respir Res.* 2019;20(1):104. doi: 10.1186/s12931-019-1078-y.
31. Calzetta L, Matera MG, Rogliani P. Monoclonal antibodies in severe asthma: is it worth it? *Expert Opin Drug Metab Toxicol.* 2019;15(6):517-520. doi: 10.1080/17425255.2019.1621837.
  32. Calzetta L, Cazzola M, Matera MG, Rogliani P. Response. *Chest.* 2019;155(5):1079-1080. doi: 10.1016/j.chest.2019.01.028.
  33. Cazzola M, Rogliani P, Calzetta L, Matera MG. Bronchodilators in subjects with asthma-related comorbidities. *Respir Med.* 2019 May;151:43-48. doi: 10.1016/j.rmed.2019.04.001.
  34. Calzetta L, Rogliani P, Page C, Rinaldi B, Cazzola M, Matera MG. Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. *Pulm Pharmacol Ther.* 2019; 56:39-50. doi: 10.1016/j.pupt.2019.03.004.
  35. Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, Ora J. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2019;20(6):737-750. doi: 10.1080/14656566.2019.1570133.
  36. Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. *Br J Pharmacol.* 2019 Oct 29. doi: 10.1111/bph.14909.
  37. Calzetta L, Matera MG, Cazzola M, Rogliani P. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. *Adv Ther.* 2019 Dec;36(12):3291-3298. doi: 10.1007/s12325-019-01119-w. Epub 2019 Oct 25.
  38. Calzetta L, Pistocchini E, Ritondo BL, Roncada P, Cito G, Britti D, Matera MG. Isolated airways in equine respiratory pharmacology: They never lie. *Pulm Pharmacol Ther.* 2019 Dec;59:101849. doi: 10.1016/j.pupt.2019.101849.
  39. Rogliani P, Matera MG, Ritondo BL, De Guido I, Puxeddu E, Cazzola M, Calzetta L. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. *Pulm Pharmacol Ther.* 2019 Dec;59:101841. doi: 10.1016/j.pupt.2019.101841.
  40. Cazzola M, Rogliani P, Stolz D, Matera MG. Pharmacological treatment and current controversies in COPD. *F1000Res.* 2019 Aug 29;8. pii: F1000 Faculty Rev-1533. doi: 10.12688/f1000research.19811.1. eCollection 2019.
  41. Cazzola M, Calzetta L, Rogliani P, Matera MG. Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD. *Expert Opin Investig Drugs.* 2019 Oct;28(10):827-833. doi: 10.1080/13543784.2019.1661990.
  42. Cazzola M, Rogliani P, Matera MG. Ultra-LABAs for the treatment of asthma. *Respir Med.* 2019 Sep;156:47-52. doi: 10.1016/j.rmed.2019.08.005.
  43. Cazzola M, Puxeddu E, Matera MG, Rogliani P. A potential role of triple therapy for asthma patients. *Expert Rev Respir Med.* 2019 Nov;13(11):1079-1085. doi: 10.1080/17476348.2019.1657408.
  44. Rogliani P, Calzetta L, Ora J, Cazzola M, Matera MG. Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. *Multidiscip Respir Med.* 2019 Aug 3;14:25. doi: 10.1186/s40248-019-0189-0. eCollection 2019. PubMed PMID: 31388422
  45. Matera MG, Rinaldi B, Calzetta L, Rogliani P, Cazzola M. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment. *Pulm Pharmacol Ther.* 2019 Oct;58:101828. doi: 10.1016/j.pupt.2019.101828.
  46. Calzetta L, Cazzola M, Matera MG, Rogliani P. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. *Chest.* 2019;155(4):758-770. doi:10.1016/j.chest.2018.12.016.
  47. Cazzola M, Page C, Calzetta L, Matera MG. Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. *Pharm Pat Anal.* 2018 Nov;7(6):249-257. doi: 10.4155/ppa-2018-0030.

48. Nigro E, Stiuso P, Matera MG, Monaco ML, Caraglia M, Maniscalco M, Perrotta F, Mazzarella G, Daniele A, Bianco A. The anti-proliferative effects of adiponectin on human lung adenocarcinoma A549 cells and oxidative stress involvement. *Pulm Pharmacol Ther.* 2019; 55:25-30. doi: A10.1016/j.pupt.2019.01.004.
49. Matera MG, Rogliani P, Ora J, Cazzola M. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. *Expert Opin Pharmacother.* 2018 Oct 25;1-11. doi: 10.1080/14656566.2018.1534957
50. Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. *Eur Respir J.* 2018 Dec 13;52(6). pii: 1801586. doi:10.1183/13993003.01586-2018.
51. Cazzola M, Matera MG. Rebuttal From Drs Cazzola and Matera. *Chest.* 2018;154(4):751-752. doi: 10.1016/j.chest.2018.06.023.
52. Cazzola M, Matera MG. POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes. *Chest.* 2018;154(4):746-748. doi: 10.1016/j.chest.2018.06.022. Matera MG, Rinaldi B, Page C, Rogliani P, Cazzola M. Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. *Expert Opin Drug Metab Toxicol.* 2018;14(10):1101-1111. doi: 10.1080/17425255.2018.1530215.
53. Calzetta L, Matera MG, Rogliani P, Cazzola M. Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease. *Expert Rev Respir Med.* 2018;12(8):693-708. doi: 10.1080/17476348.2018.1495562.
54. Cazzola M, Matera MG, Rogliani P, Calzetta L. Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach? *Expert Opin Investig Drugs.* 2018;27(7):573-581. doi: 10.1080/13543784.2018.1492548.
55. Cazzola M, Matera MG. Combining Dual Bronchodilation and  $\beta$ -Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases. *Chest.* 2018;153(6):1289-1291. doi: 10.1016/j.chest.2018.01.032.
56. Cazzola M, Matera MG. Editorial overview: Respiratory: Pulmonary pharmacology - It is time for a breath of fresh air. *Curr Opin Pharmacol.* 2018 Jun;40:iv-viii. doi: 10.1016/j.coph.2018.05.011.
57. Matera MG, Page C, Rinaldi B.  $\beta$ 2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases. *Curr Opin Pharmacol.* 2018 Jun;40:142-146. doi: 10.1016/j.coph.2018.04.012.
58. Liccardi G, Calzetta L, Milanese M, Salzillo A, Apicella G, Matera MG, Rogliani P. Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection? *J Allergy Clin Immunol Pract.* 2018 May-Jun;6(3):1093-1094. doi: 10.1016/j.jaip.2018.01.029.
59. Rogliani P, Ora J, Matera MG, Cazzola M, Calzetta L. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. *Expert Opin Drug Saf.* 2018 Jun;17(6):589-596. doi: 10.1080/14740338.2018.1472232.
60. Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG. Impact of doxofylline in COPD: A pairwise meta-analysis. *Pulm Pharmacol Ther.* 2018 Aug;51:1-9. doi: 10.1016/j.pupt.2018.04.010.
61. Calzetta L, Matera MG, Facciolo F, Cazzola M, Rogliani P. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. *Respir Res.* 2018 Apr 12;19(1):65. doi: 10.1186/s12931-018-0770-7
62. Calzetta L, Rogliani P, Facciolo F, Rinaldi B, Cazzola M, Matera MG. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation. *Biomed Pharmacother.* 2018 Jul;103:1-8. doi: 10.1016/j.biopha.2018.04.011.
63. Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. *Curr Opin Pharmacol.* 2018 Jun;40:95-103. doi: 10.1016/j.coph.2018.03.011..

64. Rogliani P, Matera MG, Puxeddu E, Mantero M, Blasi F, Cazzola M, Calzetta L. Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis. *Pulm Pharmacol Ther.* 2018 Jun;50:28-37. doi: 10.1016/j.pupt.2018.03.004.
65. Calzetta L, Rogliani P, Pistocchini E, Mattei M, Cito G, Alfonsi P, Page C, Matera MG. Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. *J Vet Pharmacol Ther.* 2018 Aug;41(4):546-554. doi: 10.1111/jvp.12504.
66. Cazzola M, Calzetta L, Matera MG, Hanania NA, Rogliani P. How does race/ethnicity influence pharmacological response to asthma therapies? *Expert Opin Drug Metab Toxicol.* 2018 Apr;14(4):435-446. doi: 10.1080/17425255.2018.1449833.
67. Matera MG, Calzetta L, Puxeddu E, Rogliani P, Cazzola M. A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. *Expert Opin Drug Saf.* 2018 May;17(5):509-517. doi: 10.1080/14740338.2018.1448786.
68. Cazzola M, Matera MG, Levi-Schaffer F, Rogliani P. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. *Expert Opin Drug Saf.* 2018 Apr;17(4):429-435. doi: 10.1080/14740338.2018.1446940.
69. Calzetta L, Matera MG, Rogliani P, Cazzola M. Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how. *Expert Rev Respir Med.* 2018 Apr;12(4):261-264. doi: 10.1080/17476348.2018.1442216.
70. Matera MG, Rogliani P, Calzetta L, Cazzola M. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma. *Expert opinion on drug metabolism & toxicology.* 2018;14:239-45. IF 3.027
71. Rogliani P, Ora J, Puxeddu E, Calzetta L, Cavalli F, Matera MG, et al. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. *Pulmonary pharmacology & therapeutics.* 2017. IF 2.525
72. Rogliani P, Ora J, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: Myth and reality. *Expert opinion on drug metabolism & toxicology.* 2017;129:117-23.
73. Matera MG, Rogliani P, Zanasi A, Cazzola M. Bronchodilator therapy for chronic cough. *Pulmonary pharmacology & therapeutics.* 2017;47:88-92
74. Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. *International journal of chronic obstructive pulmonary disease.* 2017;12:3469-85. IF 3.157
75. Matera MG, Rinaldi B, Calzetta L, Cazzola M. Assessing the viability of long-acting beta2-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. *Expert opinion on drug metabolism & toxicology.* 2017;13:129-36. IF 3.027
76. Matera MG, Rinaldi B, Calzetta L, Cazzola M. Pharmacogenetic and pharmacogenomic considerations of asthma treatment. *Expert opinion on drug metabolism & toxicology.* 2017;13:1159-67. IF 3.027
77. Matera MG, Calzetta L, Rinaldi B, Cazzola M. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. *Expert opinion on drug metabolism & toxicology.* 2017;13:1007-13. IF 3.027
78. Cazzola M, Rogliani P, Calzetta L, Lauro D, Page C, Matera MG. Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. *Trends in pharmacological sciences.* 2017;38:940-51. IF 12.797
79. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis. *Copd.* 2017;14:552-63. IF 2.576
80. Cazzola M, Calzetta L, Rogliani P, Matera MG. The Challenges of Precision Medicine in COPD. *Molecular diagnosis & therapy.* 2017;21:345-55. IF 1.909
81. Cazzola M, Calzetta L, Rinaldi B, Page C, Rosano G, Rogliani P, et al. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. *Drugs.* 2017;77:721-32. IF 5.000

82. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. *Pulmonary pharmacology & therapeutics*. 2017. IF 2.525
83. Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. *Respiratory research*. 2017;18:26. IF 3.841
84. Calzetta L, Roncada P, di Cave D, Bonizzi L, Urbani A, Pistocchini E, Rogliani P, Matera MG. Pharmacological treatments in asthma-affected horses: a pair-wise and network meta-analysis. *Equine Vet J*. 2017 Mar 10. doi: 10.1111/evj.12680. [Epub ahead of print] PubMed PMID: 28295526. IF 2.382
85. Rogliani P, Calzetta L, Coppola A, Cavalli F, Ora J, Puxeddu E, Matera MG, Cazzola M. Optimizing drug delivery in COPD: The role of inhaler devices. *Respir Med*. 2017 Mar;124:6-14. doi: 10.1016/j.rmed.2017.01.006. Review. PubMed PMID:28284323.
86. Cazzola M, Calzetta L, Rogliani P, Matera MG. The Challenges of Precision Medicine in COPD. *Mol Diagn Ther*. 2017 Feb 28. doi: 10.1007/s40291-017-0266-z.[Epub ahead of print] PubMed PMID: 28247183.
87. Cazzola M, Calzetta L, Rogliani P, Matera MG. Tiotropium formulations and safety: a network meta-analysis. *Ther Adv Drug Saf*. 2017 Jan;8(1):17-30. doi: 10.1177/2042098616667304. PubMed PMID: 28203364; PubMed Central PMCID:PMC5298465.
88. Cazzola M, Ora J, Rogliani P, Matera MG. Role of muscarinic antagonists in asthma therapy. *Expert Rev Respir Med*. 2017 Mar;11(3):239-253. doi: 10.1080/17476348.2017.1289844. PubMed PMID: 28140686.
89. Cazzola M, Calzetta L, Facciolo F, Rogliani P, Matera MG. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. *Respir Res*. 2017 Jan24;18(1):26. doi: 10.1186/s12931-016-0500-y. PubMed PMID: 28118826; PubMed Central PMCID: PMC5260037.
90. Bianco A, Nigro E, Monaco ML, Matera MG, Scudiero O, Mazzarella G, Daniele A. The burden of obesity in asthma and COPD: Role of adiponectin. *Pulm Pharmacol Ther*. 2017 Apr;43:20-25. doi: 10.1016/j.pupt.2017.01.004. Review. PubMed PMID: 28115224.
91. Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. *Eur Respir Rev*. 2017 Jan 17;26(143). pii: 160043. doi: 10.1183/16000617.0043-2016. Review. PubMed PMID: 28096283.
92. Matera MG, Cazzola M. Muscarinic Receptor Antagonists. *Handb Exp Pharmacol*. 2017;237:41-62. doi: 10.1007/164\_2016\_68. PubMed PMID: 27787709. 10: Cazzola M, Matera MG. Fixed-Dose Combination Inhalers. *Handb Exp Pharmacol*. 2017;237:117-129. doi: 10.1007/164\_2016\_66. PubMed PMID: 27783268.
93. Matera MG, Rinaldi B, Calzetta L, Cazzola M. Assessing the viability of long-acting  $\beta(2)$ -agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. *Expert Opin Drug Metab Toxicol*. 2017 Feb;13(2):129-136. doi: 10.1080/17425255.2017.1234604. Review. PubMed PMID: 27615145.
94. Matera MG, Page C, Rogliani P, Calzetta L, Cazzola M. Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. *Drugs*. 2016 Sep;76(13):1257-70. doi: 10.1007/s40265-016-0625-9. Review. PubMed PMID: 27506851.
95. Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, Matera MG. GLP1-R: a Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. *Am J Respir Cell Mol Biol*. 2016 Jul 22. [Epub ahead of print] PubMed PMID: 27447052.
96. Calzetta L, Rogliani P, Matera MG, Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. *Chest*. 2016 May;149(5):1181-96. doi: 10.1016/j.chest.2016.02.646. PubMed PMID: 26923629.
97. Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, Matera MG. Interaction between corticosteroids and muscarinic antagonists in human airways. *Pulm Pharmacol Ther*. 2016 Feb;36:1-9. doi: 10.1016/j.pupt.2015.11.004. PubMed PMID: 26656790.

98. Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in COPD: the role of NAC. *Expert Rev Respir Med.* 2016;10(1):89-97. doi:10.1586/17476348.2016.1121105. Review. PubMed PMID: 26567752.
99. Matera MG, Cazzola M. Muscarinic Receptor Antagonists. *Handb Exp Pharmacol.* 2016 Oct 28. [Epub ahead of print] PubMed PMID: 27787709.
100. Cazzola M, Matera MG. Fixed-Dose Combination Inhalers. *Handb Exp Pharmacol.* 2016 Oct 26. [Epub ahead of print] PubMed PMID: 27783268.
101. Matera MG, Rinaldi B, Calzetta L, Cazzola M. Assessing the viability of long-acting  $\beta(2)$ -agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective. *Expert Opin Drug Metab Toxicol.* 2016 Sep 14:1-8. [Epub ahead of print] PubMed PMID: 27615145.
102. Matera MG, Page C, Rogliani P, Calzetta L, Cazzola M. Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. *Drugs.* 2016 Sep;76(13):1257-70. doi: 10.1007/s40265-016-0625-9. Review. PubMed PMID:27506851.
103. Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. *Respir Med.* 2016 Aug;117:190-7. doi: 10.1016/j.rmed.2016.06.015. Epub 2016 Jun 16. Review. PubMed PMID: 27492531.
104. Liccardi G, Salzillo A, Calzetta L, Cazzola M, Matera MG, Rogliani P. Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. *Respir Med.* 2016 Aug;117:150-3. doi: 10.1016/j.rmed.2016.05.026. Epub 2016 May 30. PubMed PMID: 27492525.
105. Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *Pulm Pharmacol Ther.* 2016 Jul 29. pii: S1094-5539(16)30061-X. doi: 10.1016/j.pupt.2016.07.009. [Epub ahead of print] PubMed PMID: 27481628.
106. Lacedonia D, Nigro E, Matera MG, Scudiero O, Monaco ML, Polito R, Carpagnano GE, Foschino Barbaro MP, Mazzarella G, Bianco A, Daniele A. Evaluation of adiponectin profile in Italian patients affected by obstructive sleep apnea syndrome. *Pulm Pharmacol Ther.* 2016 Jul 25. pii: S1094-5539(16)30059-1. doi: 10.1016/j.pupt.2016.07.008. [Epub ahead of print] PubMed PMID: 27470682.
107. Calzetta L, Orlandi A, Page C, Rogliani P, Rinaldi B, Rosano G, Cazzola M, Matera MG. Brain natriuretic peptide: Much more than a biomarker. *Int J Cardiol.* 2016 Oct 15;221:1031-8. doi: 10.1016/j.ijcard.2016.07.109. Epub 2016 Jul 9. Review. PubMed PMID: 27447810.
108. Liccardi G, Salzillo A, Calzetta L, Ora J, Cazzola M, Matera MG, Rogliani P. Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? *J Allergy Clin Immunol Pract.* 2016 Jul-Aug;4(4):791-3. doi: 10.1016/j.jaip.2016.03.025. PubMed PMID: 27393788.
109. Pelaia G, Vatrella A, Busceti MT, Fabiano F, Terracciano R, Matera MG, Maselli R. Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma. *Pulm Pharmacol Ther.* 2016 Jul 2. pii: S1094-5539(16)30052-9. doi: 10.1016/j.pupt.2016.07.001. [Epub ahead of print] Review. PubMed PMID: 27381656.
110. Cazzola M, Calzetta L, Puxeddu E, Ora J, Facciolo F, Rogliani P, Matera MG. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. *Respir Res.* 2016 Jun 13;17(1):70. doi: 10.1186/s12931-016-0386-8. PubMed PMID: 27296533; PubMed Central PMCID: PMC4906998.
111. Rogliani P, Calzetta L, Cazzola M, Matera MG. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis. *Expert Opin Drug Saf.* 2016 Aug;15(8):1133-46. doi: 10.1080/14740338.2016.1199683. Epub 2016 Jun 20. PubMed PMID: 27279341.
112. Calzetta L, Rinaldi B, Cazzola M, Matera MG. Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma. *Expert Opin Drug*



- Metab Toxicol. 2016 Jul;12(7):813-22. doi: 10.1080/17425255.2016.1192125. Epub 2016 Jun 9. PubMed PMID: 27253498.
113. Cazzola M, Calzetta L, Rogliani P, Matera MG. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease. *Expert Opin Drug Discov.* 2016 Jul;11(7):733-44. doi: 10.1080/17460441.2016.1184642. Epub 2016 May 21. PubMed PMID: 27169612.
  114. Matera MG, Sanduzzi A, Alfano R, Cazzola M. Acridinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema. *Expert Rev Clin Pharmacol.* 2016 Jun;9(6):771-7. doi: 10.1586/17512433.2016.1169173. Epub 2016 Apr 7. PubMed PMID: 26998725.
  115. Matera MG, Rogliani P, Calzetta L, Cazzola M. Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update. *Drug Saf.* 2016 Jun;39(6):501-8. doi: 10.1007/s40264-016-0402-4. Review. PubMed PMID: 26924197.
  116. Cazzola M, Rogliani P, Ora J, Matera MG. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2016;17(7):977-88. doi: 10.1517/14656566.2016.1155555. Epub 2016 Mar 21. PubMed PMID: 26894516.
  117. Matera MG, Sanduzzi A, Cazzola M. Specific role of combination acridinium: formoterol in the treatment of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2016 Jan 5;11:73-9. doi: 10.2147/COPD.S78000. eCollection 2016. Review. PubMed PMID: 26792987; PubMed Central PMCID: PMC4708173.
  118. Matera MG, Ora J, Cazzola M. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. *Ther Clin Risk Manag.* 2015 Dec 4;11:1805-11. doi: 10.2147/TCRM.S73581. eCollection 2015. Review. PubMed PMID: 26676161; PubMed Central PMCID: PMC4675639.
  119. Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, Matera MG. Interaction between corticosteroids and muscarinic antagonists in human airways. *Pulm Pharmacol Ther.* 2016 Feb;36:1-9. doi: 10.1016/j.pupt.2015.11.004. Epub 2015 Nov 30. PubMed PMID: 26656790.
  120. Matera MG, Calzetta L, Cazzola M. Oxidation pathway and exacerbations in COPD: the role of NAC. *Expert Rev Respir Med.* 2016;10(1):89-97. doi: 10.1586/17476348.2016.1121105. Epub 2015 Dec 15. Review. PubMed PMID: 6567752.
  121. Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. *Drugs Today (Barc).* 2015 ug;51(8):469-78. doi: 10.1358/dot.2015.51.8.2365401. PubMed PMID: 26380385.
  122. Calzetta L, Soggiu A, Roncada P, Bonizzi L, Pistocchini E, Urbani A, Rinaldi B, Matera MG. Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia. *Eur J Pharmacol.* 2015 Oct 15;765:463-71. doi: 10.1016/j.ejphar.2015.09.007. Epub 2015 Sep 11. PubMed PMID: 26368667.
  123. Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. *Eur Respir Rev.* 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Review. PubMed PMID: 26324807.
  124. Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. *Drugs.* 2015 Sep;75(14):1575-85. doi:10.1007/s40265-015-0450-6. PubMed PMID: 26316169.
  125. Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between acridinium and formoterol: From bench to bedside. *Respir Med.* 2015 Oct;109(10):1305-11. doi: 10.1016/j.rmed.2015.08.005. Epub 2015 Aug 13. PubMed PMID: 26303336.
  126. Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol.* 2015;8(5):529-39. doi: 10.1586/17512433.2015.1075389. Review. PubMed PMID: 26294073.

127. Cazzola M, Coppola A, Rogliani P, Matera MG. Novel glucocorticoid receptor agonists in the treatment of asthma. *Expert Opin Investig Drugs*.2015;24(11):1473-82. doi: 10.1517/13543784.2015.1078310. Epub 2015 Aug 19. Review. PubMed PMID: 26293110.
128. Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients with COPD. *Lancet Respir Med*. 2015 Aug;3(8):593-5. doi: 10.1016/S2213-600(15)00279-9. Epub 2015 Jul 22. PubMed PMID: 26208993.
129. Cazzola M, Calzetta L, Matera MG, Muscoli S, Rogliani P, Romeo F. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. *Respir Med*. 2015 Aug;109(8):1019-25. doi: 10.1016/j.rmed.2015.05.021. Epub 2015 Jun 23. PubMed PMID: 26111914.
130. Cazzola M, Rogliani P, Sanduzzi A, Matera MG. Influence of ethnicity on response to asthma drugs. *Expert Opin Drug Metab Toxicol*. 2015 Jul;11(7):1089-97. doi: 10.1517/17425255.2015.1047341. Epub 2015 May 20. Review. PubMed PMID:25995058.
131. Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. *Eur J Pharmacol*. 2015 Aug 15;761:168-73. doi: 10.1016/j.ejphar.2015.05.020. Epub 2015 May 14. Review. PubMed PMID: 25981302.
132. Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, Cazzola M. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. *Eur J Pharmacol*. 2015 May 5. pii: S0014-2999(15)00404-5. doi: 10.1016/j.ejphar.2015.04.042.
133. Calzetta L, Luongo L, Cazzola M, Page C, Rogliani P, Facciolo F, Maione S, Capuano A, Rinaldi B, Matera MG. Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. *Life Sci*. 2015 Jun 15;131:44-50. doi: 10.1016/j.lfs.2015.03.023.
134. Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. *Pulm Pharmacol Ther*. 2015 Apr 18. pii: S1094-5539(15)00042-5. doi: 10.1016/j.pupt.2015.03.007.
135. Matera MG, Rogliani P, Cazzola M. QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2015 May;16(7):1079-90. doi: 10.1517/14656566.2015.1032247
136. Rinaldi B, Donniacuo M, Sodano L, Gritti G, Martuscelli E, Orlandi A, Rafaniello C, Rossi F, Calzetta L, Capuano A, Matera MG. Effects of chronic treatment with the new ultra-long-acting  $\beta_2$  -adrenoceptor agonist indacaterol alone or in combination with the  $\beta_1$  -adrenoceptor blocker metoprolol on cardiac remodelling. *Br J Pharmacol*. 2015 Mar 30. doi: 10.1111/bph.13148.
137. Cazzola M, Calzetta L, Matera MG. Aclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary disease. *Drugs Today (Barc)*. 2015 Feb;51(2):97-105. doi: 10.1358/dot.2015.51.2.2273382. PMID:25756065
138. Orlandi A, Calzetta L, Doldo E, Tarquini C, Matera MG, Passeri D. Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells. *Pulm Pharmacol Ther*. 2015 Apr;31:51-4. doi: 10.1016/j.pupt.2015.02.005.
139. Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. *Pulm Pharmacol Ther*. 2015 Apr;31:15-27. doi: 10.1016/j.pupt.2015.01.005.
140. Matera MG, Cardaci V, Cazzola M, Rogliani P. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. *Expert Opin Drug Saf*. 2015 Apr;14(4):533-41. doi: 10.1517/14740338.2015.1001363.
141. Matera MG, Cardaci V, Cazzola M, Rogliani P. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease *Expert Opin Drug Saf*. 2015 Jan 5:1-9. [Epub ahead of print]

142. Matera MG, Capuano A, Cazzola M Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. *Expert Rev Respir Med.* 2014 Dec 6:1-8. [Epub ahead of print] ISSN 1747-6348
143. Pelaia G, Maselli R, Matera MG. Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium. *Pharmacology.* 2014 Nov 28;94(5-6):249-258. DOI: 10.1159/issn.0031-7012 -e-ISSN: 1423-0313 (Online)
144. Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. *Eur J Pharmacol.* 2014 Dec 15;745:135-43. doi: 10.1016/j.ejphar.2014.10.025. Epub 2014 Oct 22. ISSN 0014-2999
145. Matera MG, Rogliani P, Cazzola M. Indacaterol for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2015 Jan;16(1):107-15. doi: 10.1517/14656566.2015.983076. Epub 2014 Nov 24. ISSN 1465-6566
146. Matera MG, Rogliani P, Rinaldi B, Cazzola M Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol.* 2015 Jan;8(1):35-41. doi: 10.1586/17512433.2015.977256. Epub 2014 Nov 8. ISSN. 1751-2433
147. Cazzola M, Matera MG Triple combinations in chronic obstructive pulmonary disease - is three better than two? *Expert Opin Pharmacother.* 2014 Dec;15(17):2475-8. doi: 10.1517/14656566.2014.972367. Epub 2014 Oct 18. ISSN 1465-6566
148. Matera MG, Rogliani P, Calzetta L, Cazzola M. Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? *Drugs.* 2014 Nov;74(17):1983-92. doi: 10.1007/s40265-014-0303-8. ISSN 0012-6667
149. Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. *COPD.* 2014 Sep 15. [Epub ahead of print] ISSN: 1541-2555
150. Matera MG, Page C, Cazzola M PDE inhibitors currently in early clinical trials for the treatment of asthma. *Expert Opin Investig Drugs.* 2014 Sep;23(9):1267-75. doi: 10.1517/13543784.2014.921157. Epub 2014 May 28. ISSN: 1354-3784
151. Rinaldi B, Capuano A, Gritti G, Donniacuo M, Scotto Di Vettimo A, Sodano L, Rafaniello C, Rossi F, Matera MG. Effects of chronic administration of  $\beta$ -blockers on airway responsiveness in a murine model of heart failure. *Pulm Pharmacol Ther.* 2014 21. pii: S1094-5539(14)00043-1. doi: 10.1016/j.pupt.2014.04.005. ISSN 1094-5539
152. Calzetta L, Rogliani P, Cazzola M, Matera MG. Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. *Expert Opin Drug Discov.* 2014 Jun;9(6):595-607. doi: 10.1517/17460441.2014.909403 ISSN: 1746-0441
153. Matera MG, Calzetta L, Rogliani P, Cesario A, Cazzola M. New Treatments for COPD in the Elderly. *Curr Pharm Des.* 2014 Mar 14. DOI: 10.2174/1381612820666141024154427 ISSN 1381-6128
154. Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2014 May;15(7):961-77. doi: 10.1517/14656566.2014.899581. Epub 2014 Mar 26. ISSN: 1465-6566
155. Cazzola M, Matera MG. N-acetylcysteine in COPD may be beneficial, but for whom? *Lancet Respir Med.* 2014 Mar;2(3):166-7. doi: 10.1016/S2213-2600(13)70294-7. ISSN 2213-2600.
156. Cazzola M, Matera MG. Bronchodilators: current and future. *Clin Chest Med.* 2014 Mar;35(1):191-201. doi: 10.1016/j.ccm.2013.10.005. ISSN 0272-5231.
157. Cazzola M, Calzetta L, Page CP, Matera MG. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. *Expert Opin Drug Metab Toxicol.* 2014 Jan;10(1):129-37. doi: 10.1517/17425255.2014.865723. Epub 2013 Dec 3. ISSN 1742-5255
158. Calzetta L, Passeri D, Kanabar V, Rogliani P, Page C, Cazzola M, Matera MG, Orlandi A. Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism. *Am J Respir Cell Mol Biol.* 2014;50:493-501. doi: 10.1165/rcmb.2013-0119OC. IF 5,125 ISSN 1044-1549

159. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. *Drug Des Devel Ther.* 2013 Oct 10;7:1201-8. doi: 10.2147/DDDT.S39449. eCollection 2013. ISSN1177-8881
160. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Dec;14(18):2489-99. doi: 10.1517/14656566.2013.848856. Epub 2013 Oct 21. ISSN 1465-6566
161. Matera MG, Calzetta L, Cazzola M.  $\beta$ -Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives. *Drugs.* 2013 Oct;73(15):1653-63. doi: 10.1007/s40265-013-0120-5. ISSN-00126667
162. Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. *J Pharmacol Exp Ther.* 2013;346:414-23. doi: 10.1124/jpet.113.204644. Epub 2013 Jun 13 I.F. 4,335 ISSN 0002-3563
163. Miraglia del Giudice M, Matera MG, Capristo C, Conte M, Santaniello F, Chinellato I, Leonardi S, Miraglia del Giudice MC, Perrone L. LABAs in asthmatic children: highlights and new inside. *Pulm Pharmacol Ther.* 2013 Oct;26(5):540-3. doi: 10.1016/j.pupt.2013.04.002. Epub 2013 Apr 11. ISSN 1094-5539
164. Cazzola M, Page CP, Matera MG. Acridinium bromide for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. ISSN 1465-6566
165. Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. *Respir Med.* 2013 Jun;107(6):848-53. doi: 10.1016/j.rmed.2013.02.008. Epub 2013 Mar 11. ISSN 0954-6111
166. Cazzola M, Rogliani P, Matera MG. Acridinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. *Expert Opin Pharmacother.* 2013 Apr;14(6):775-81. doi: 10.1517/14656566.2013.776539.
167. Cazzola M, Page CP, Rogliani P, Matera MG  $\beta$ 2-agonist therapy in lung disease. *Am J Respir Crit Care Med.* 2013;187(7):690-6. doi: 10.1164/rccm.201209-1739PP IF 11.041 ISSN1073-444X
168. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. *Pulm Pharmacol Ther.* 2013 Jun;26(3):307-17. doi: 10.1016/j.pupt.2012.12.006.
169. Rogliani P, Calzetta L, Rendina EA, Massullo D, Dauri M, Rinaldi B, Capuano A, Matera MG. The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle. *Pulm Pharmacol Ther.* 2013; 26:325-31 doi: 10.1016/j.pupt.2014.04.005. ISSN 1094-5539 Med. 2013
170. Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. *Pulm Pharmacol Ther.* 2013 Jun;26(3):307-17. doi: 10.1016/j.pupt.2012.12.006. Epub 2012 Dec 27. ISSN 1094-5539
171. Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. *Respir Med.* 2013 Jan;107(1):107-11. doi: 10.1016/j.rmed.2012.09.022. ISSN0854-6111
172. Matera MG, Calzetta L, Passeri D, Rogliani P, Orlandi A. Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. *Pulm Pharmacol Ther.* 2012 Sep 21. pii: S1094-5539(12)00140-X. doi: 10.1016/j.pupt.2012.09.003. ISSN 1094-5539
173. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. *Expert Opin Investig Drugs.* 2012 Oct;21(10):1489-501. EpubIF5.274
174. Cazzola M, Calzetta L, Rogliani P, Lauro D, Novelli L, Page CP, Kanabar V, Matera MG. High Glucose Enhances Responsiveness of Human Airways Smooth Muscle via the Rho/ROCK Pathway. *Am J Respir Cell Mol Biol.* 2012 Oct;47(4):509-16. doi: 10.1165/rcmb.2011-0449OC.

175. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. *Pharmacol Rev.* 2012; 64:450-504. doi: 10.1016/j.pupt.2012.12.006. ISSN 0031-6997
176. Cazzola M, Matera MG. Lung blood flow must be considered when prescribing a long-acting  $\beta$ 2-agonist/inhaled corticosteroid combination. *Chest.* 2012 May;141(5):1134-6. doi: 10.1378/chest.11-2497 ISSN: 00123692
177. Matera MG, Calzetta L, Rinaldi B, Cazzola M. Treatment of COPD: moving beyond the lungs. *Curr Opin Pharmacol.* 2012 Jun;12(3):315-22. doi: 10.1016/j.coph.2012.04.001. Epub 2012 ISSN 1471-4892
178. Matera MG, Cazzola M. Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies. *Curr Opin Pharmacol.* 2012 Jun;12(3):225-8. doi: 10.1016/j.coph.2012.03.006. Epub 2012 Apr 11. ISSN 1471-4892
179. Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. *Eur Respir J.* 2012 Sep;40(3):724-41. doi: 10.1183/09031936.00213711. ISSN 0903-1936
180. Cazzola M, Matera MG. IL-17 in chronic obstructive pulmonary disease. *Expert Rev Respir Med.* 2012 Apr;6(2):135-8. doi: 10.1586/ers.12.7. ISSN: 1747-6348
181. Cazzola M, Capuano A, Rogliani P, Matera MG. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. *Curr Opin Pharmacol.* 2012 Jun;12(3):300-8. doi: 10.1016/j.coph.2012.01.019. ISSN 1471-4892
182. Matera MG, Calzetta L, Segreti A, Cazzola M. Emerging drugs for chronic obstructive pulmonary disease. *Expert Opin Emerg Drugs.* 2012 Mar;17(1):61-82. doi: 10.1517/14728214.2014.983295. ISSN: 1472-8214
183. Cazzola M, Matera MG. Tremor and  $\beta$ (2)-adrenergic agents: is it a real clinical problem? *Pulm Pharmacol Ther.* 2012 Feb;25(1):4-10. doi: 10.1016/j.pupt.2012.09.003. ISSN 1094-5539
184. Hewson CA, Patel S, Calzetta L, Campwala H, Havard S, Luscombe E, Clarke PA, Peachell PT, Matera MG, Cazzola M, Page C, Abraham WM, Williams CM, Clark JD, Liu WL, Clarke NP, Yeadon M. Preclinical evaluation of an inhibitor of cytosolic phospholipase A2 $\alpha$  for the treatment of asthma. *J Pharmacol Exp Ther.* 2012 Mar;340(3):656-65. doi: 10.1124/jpet.111.186379 ISSN - 3563002
185. Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study *Respir Med.* 2012 Feb;106(2):249-56. doi: 10.1016/j.rmed.2011.07.021 ISSN 0954-5539
186. Cazzola M, Matera MG. Inhibiting or blocking LIGHT, a TNF superfamily member, for treating airway remodeling. *Expert Rev Respir Med.* 2011 Oct;5(5):623-5. doi: 10.1586/ers.11.65
187. Calzetta L, Spina D, Cazzola M, Page CP, Facciolo F, Rendina EA, Matera MG. Pharmacological characterization of adenosine receptors on isolated human bronchi. *Am J Respir Cell Mol Biol.* 2011 Dec;45(6):1222-31. doi: 10.1165/rcmb.2011-0056OC
188. Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. *Trends Pharmacol Sci.* 2011 Aug;32(8):495-506. doi: 10.1016/j.tips.2011.04.003
189. Matera MG, Calzetta L, Passeri D, Facciolo F, Rendina EA, Page C, Cazzola M, Orlandi A. Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. *Br J Pharmacol.* 2011 Aug;163(8):1740-54. doi: 10.1111/j.1476-5381.2011.01339.x
190. Cazzola M, Calzetta L, Page CP, Rinaldi B, Capuano A, Matera MG. Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. *Am J Respir Cell Mol Biol.* 2011 Oct;45(4):704-10. doi: 10.1165/rcmb.2010-0306OC.
191. Cazzola M, Calzetta L, Matera MG.  $\beta$ (2) -adrenoceptor agonists: current and future direction. *Br J Pharmacol.* 2011 May;163(1):4-17. doi: 10.1111/j.1476-5381.2011.01216.x

192. Matera MG, Calzetta L, Rogliani P, Bardaro F, Page CP, Cazzola M. Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. *Pulm Pharmacol Ther.* 2011 Apr;24(2):221-6. doi: 10.1016/j.pupt.2010.12.008.
193. Cazzola M, Tompkins TA, Matera MG. Immunomodulatory impact of a synbiotic in T(h)1 and T(h)2 models of infection. *Ther Adv Respir Dis.* 2010 Oct;4(5):259-70. doi: 10.1177/1753465810379009
194. Cazzola M, Pasqua F, Ferri L, Biscione G, Cardaci V, Matera MG. Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. *Pulm Pharmacol Ther.* 2011 Feb;24(1):118-22. doi: 00.1016/j.pupt.2010.08.005.
195. Tannu SA, Renzetti LM, Tare N, Ventre JD, Lavelle D, Lin TA, Morschauser A, Paciorek J, Bolin DR, Michel H, Singer L, Hargaden M, Knowles I, Gardiner P, Cazzola M, Calzetta L, Matera MG, Hicks A. Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors. *Br J Pharmacol.* 2010 Nov;161(6):1329-42. doi: 10.1111/j.1476-5381.2010.00975.x
196. Cazzola M, Calzetta L, Matera MG. The cardiovascular risk of tiotropium: is it real? *Expert Opin Drug Saf.* 2010 Sep;9(5):783-92. doi: 10.1517/14740338.2010.500611
197. Cazzola M, Segreti A, Stirpe E, Appodia M, Senis L, Matera MG. Energy expenditure and impact of bronchodilators in COPD patients. *Respir Med.* 2010 Oct;104(10):1490-4. doi: 10.1016/j.rmed.2010.04.002
198. Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). *Drugs Today (Barc).* 2010 Mar;46(3):139-50. doi: 10.1358/dot.2010.46.3.1450070
199. Cazzola M, Hanania NA, Matera MG. Arformoterol tartrate in the treatment of COPD. *Expert Rev Respir Med.* 2010 Apr;4(2):155-62. doi: 10.1586/ers.10.16
200. Cazzola M, Picciolo S, Matera MG. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. *Expert Opin Pharmacother.* 2010 Feb;11(3):441-9. doi: 10.1517/14656560903555201
201. Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. *Pulm Pharmacol Ther.* 2010 Apr;23(2):121-8. doi: 10.1016/j.pupt.2009.10.007
202. Matera MG, Martuscelli E, Cazzola M. Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. *Pulm Pharmacol Ther.* 2010 Feb;23(1):1-8. doi: 10.1016/j.pupt.2009.10.001
203. Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. *Curr Opin Pulm Med.* 2010 Jan;16(1):6-12. doi: 10.1097/MCP.0b013e32833303d2
204. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. *Eur Respir J.* 2009 Sep;34(3):757-69. doi: 10.1183/09031936.00013109
205. Matera MG, Calzetta L, Parascandolo V, Curradi G, Rogliani P, Cazzola M. Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. *Pulm Pharmacol Ther.* 2009 Dec;22(6):478-82. doi: 10.1016/j.pupt.2009.04.005
206. Cazzola M, Matera MG. Treatment of asthma during pregnancy: more solid evidence needed. *Thorax.* 2008 Nov;63(11):944-5. doi: 10.1136/thx.2008.104463.
207. Cazzola M, Matera MG. Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution. *Am J Respir Crit Care Med.* 2008 Oct 1;178(7):661-2. doi: 10.1164/rccm.200806-963ED.
208. Cazzola M, Matera MG. To add, or not to add an inhaled corticosteroid in moderate COPD: that is the question. *Chest.* 2008 Aug;134(2):223-5. doi: 10.1378/chest.08-0855.
209. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. *Br J Pharmacol.* 2008 Oct;155(3):291-9. doi: 10.1038/bjp.2008.284
210. Matera MG, Curradi G, Cazzola M. Long-acting beta(2) agonists in asthma and allergic rhinitis. *Expert Opin Pharmacother.* 2008 Jun;9(9):1531-9. doi: 10.1517/14656566.9.9.1531

211. Matera MG, Calzetta L, Sanduzzi A, Page CP, Cazzola M. Effects of neuraminidase on equine isolated bronchi. *Pulm Pharmacol Ther.* 2008 Aug;21(4):624-9. doi: 10.1016/j.pupt.2008.02.003.
212. Cazzola M, Ciapriani C, Page CP, Matera MG. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease. *Expert Opin Ther Targets.* 2007 Oct;11(10):1273-86.
213. Cazzola M, Matera MG. Safety of long-acting beta2-agonists in the treatment of asthma. *Ther Adv Respir Dis.* 2007 Oct;1(1):35-46. doi: 10.1177/1753465807081747.
214. Cazzola M, Gabriella Matera M. The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study. *Respir Med.* 2007 May;101(5):957-62.
215. Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. *Trends Pharmacol Sci.* 2007 Oct;28(10):544-50.
216. Matera MG, Cazzola M. ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? *Drugs.* 2007;67(4):503-15.
217. Matera MG, Polosa R. Adenosine receptors: novel targets for drug development in allergic rhinitis. *Clin Exp Allergy.* 2007 Jan;37(1):4-7.
218. Brown RA, Allegra L, Matera MG, Page CP, Cazzola M. Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. *Pulm Pharmacol Ther.* 2006;19(6):419-24.
219. Matera MG. Pharmacologic characteristics of prulifloxacin. *Pulm Pharmacol Ther.* 2006;19 Suppl 1:20-9.
220. Santus P, Centanni S, Verga M, Di Marco F, Matera MG, Cazzola M. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. *Respir Med.* 2006 Jul;100(7):1277-81.
221. Bellia V, Battaglia S, Matera MG, Cazzola M. The use of bronchodilators in the treatment of airway obstruction in elderly patients. *Pulm Pharmacol Ther.* 2006;19(5):311-9.
222. Cazzola M, Matera MG, Donnarumma G, Tufano MA, Sanduzzi A, Marchetti F, Blasi F. Pharmacodynamics of levofloxacin in patients with acute exacerbation of chronic bronchitis. *Chest.* 2005 Oct;128(4):2093-8.
223. Matera MG, Sanduzzi A, Ponticiello A, Vatrella A, Salzillo A, Cazzola M. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses. *Respiration.* 2005 Sep-Oct;72(5):466-70.
224. Matera MG, Calzetta L, Peli A, Scagliarini A, Matera C, Cazzola M. Immune sensitization of equine bronchus: glutathione, IL-1beta expression and tissue responsiveness. *Respir Res.* 2005 Sep 15;6:104.
225. Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. *Drugs.* 2005;65(12):1595-610.
226. Cazzola M, Matera MG, Lötvall J. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. *Expert Opin Investig Drugs.* 2005 Jul;14(7):775-83.
227. Cazzola M, Noschese P, De Michele F, D'Amato G, Matera MG. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. *Respir Med.* 2006 Feb;100(2):212-7.
228. Cazzola M, Matera MG, Pezzuto G. Inflammation--a new therapeutic target in pneumonia. *Respiration.* 2005 Mar-Apr;72(2):117-26.
229. Cazzola M, Noschese P, Salzillo A, De Giglio C, D'Amato G, Matera MG. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. *Respir Med.* 2005 May;99(5):524-8.
230. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, Matera MG. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. *Respir Med.* 2004 Dec;98(12):1214-21.

231. Cazzola M, Santus P, Di Marco F, Carlucci P, Mondoni M, Matera MG, Centanni S. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. *Pulm Pharmacol Ther.* 2004;17(3):121-5.
232. Cazzola M, Matera MG, Ruggeri P, Sanduzzi A, Spicuzza L, Vatrella A, Girbino G. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. *Respiration.* 2004 Mar-Apr;71(2):159-64.
233. Cazzola M, Matera MG, Blasi F. Macrolide and occult infection in asthma. *Curr Opin Pulm Med.* 2004 Jan;10(1):7-14.
234. Cazzola M, Blasi F, Terzano C, Matera MG, Marsico SA. Delivering antibacterials to the lungs: considerations for optimizing outcomes. *Am J Respir Med.* 2002;1(4):261-72.
235. Cazzola M, Matera MG. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD. *Chest.* 2004 Jan;125(1):9-11.
236. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, Centanni S. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. *Pulm Pharmacol Ther.* 2004;17(1):35-9.
237. Cazzola M, Matera MG. Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD. *Pulm Pharmacol Ther.* 2003;16(4):197-201.
238. Cazzola M, Page CP, Matera MG. Alternative and/or integrative therapies for pneumonia under development. *Curr Opin Pulm Med.* 2004 May;10(3):204-10
239. Cazzola M, Matera MG, Page CP. Novel approaches to the treatment of pneumonia. *Trends Pharmacol Sci.* 2003 Jun;24(6):306-14.
240. Cazzola M, Sanduzzi A, Matera MG. Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections. *Pulm Pharmacol Ther.* 2003;16(3):131-45.
241. Cazzola M, Santus P, Matera MG, Carlucci P, Belloli E, Di Marco F, Centanni S. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. *Respir Med.* 2003 May;97(5):458-62.
242. Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. *Respir Med.* 2003 May;97(5):453-7.
243. Cazzola M, Matera MG, D'Amato M, Califano C, Sanduzzi A, Vatrella A, D'Amato G. Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. *Pulm Pharmacol Ther.* 2003;16(2):105-9.
244. Matera MG, Amorena M, Lucisano A. Innervation of equine airways. *Pulm Pharmacol Ther.* 2002;15(6):503-11.
245. Cazzola M, Califano C, Di Perna F, D'Amato M, Terzano C, Matera MG, D'Amato G, Marsico SA. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD. *Respir Med.* 2002 Oct;96(10):790-5.
246. Spicuzza L, Basile L, Belvisi MG, Bellofiore S, Matera MG, Cazzola M, Di Maria GU. The protective role of epithelium-derived nitric oxide in isolated bovine trachea. *Pulm Pharmacol Ther.* 2002;15(4):357-62.
247. Cazzola M, Santus P, Castagna F, Di Marco F, Terzano C, Matera MG, Centanni S. Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD. *Respir Med.* 2002 Jun;96(6):439-43.
248. Cazzola M, Grella E, Matera MG, Mazzarella G, Marsico SA. Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. *Pulm Pharmacol Ther.* 2002;15(2):97-102.
249. Cazzola M, D'Amato M, Califano C, Di Perna F, Calderaro E, Matera MG, D'Amato G. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. *Clin Ther.* 2002 Apr;24(4):595-604.
250. Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. *Clin Pharmacokinet.* 2002;41(1):19-30.



251. Cazzola M, Noschese P, D'Amato G, Matera MG. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest. 2002 Jan;121(1):230-41.
252. Cazzola M, Di Perna F, D'Amato M, Califano C, Matera MG, D'Amato G. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med. 2001 Nov;95(11):917-21.
253. Cazzola M, Centanni S, Boveri B, Di Marco F, Santus P, Matera MG, Allegra L. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Respiration. 2001;68(5):452-9.
254. Cazzola M, Matera MG, Tufano MA, Catalanotti P, Polverino M, Cantoni V, Fici F, Sarlo F, Rossi F. Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study. J Chemother. 2001 Aug;13(4):407-12.
255. Cazzola M, Matera MG, Noschese P. Parenteral antibiotic therapy in the treatment of lower respiratory tract infections. Strategies to minimize the development of antibiotic resistance. Pulm Pharmacol Ther. 2000;13(6):249-56.
256. Cazzola M, Matera MG, Di Perna E, Califano C, D'Amato M, Mazzarella G. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med. 1999 Dec;93(12):909-11.
257. Cazzola M, Matera MG. 5-HT modifiers as a potential treatment of asthma. Trends Pharmacol Sci. 2000 Jan;21(1):13-6.

I authorize the processing of personal data contained in my curriculum vitae on the basis of D. Lgs. 196 30 June 2003

FIRMA  
